Company
Immunis
Immunis, Inc., a clinical-stage biotechnology company developing off-the-shelf multi-active biologics for muscle health and healthy aging
Also known as Immunis, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Irvine, California, United States
- Legal name
- Immunis, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Immunis, Inc., a clinical-stage biotech pioneering multi-active stem cell-derived biologics for age and disease-related immune dysregulation
Funding snapshot
- Total raised
- $32.4MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Series A, $25M2025-01-11
Funding rounds
- Round, 2026
- $12M2026-05-28, SEC form D sold, 12 investors
- Series A
- $25M2025-01-11, Company stated
- Round, 2024
- $20.4M2024-06-17, SEC form D sold, 27 investors
Loading relationship preview